Search results for: Recombinant Human Factor VIII Proteins
#31556206 // Save this To Up
Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A (PWHA). However, FVIIIs are neutralized if anti-FVIII-antibodies (inhibitors) develop. Accumulating evidence suggests that pdFVIIIs with von Willebrand factor (VWF) are less immunogenic than rFVIIIs and that distinct rFVIIIs are differentially immunogenic. Since inhibitor development is T-helper-cell-dependent, human leukocyte antigen (HLA)-class-II (HLAcII) molecules constitute an important early determinant.
1833 related Products with: Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Recombinant Human Intrins Rabbit Anti-factor VIII(F Macrophage Colony Stimula Rat Anti-Mouse Dendritic Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F FDA Standard Frozen Tissu
#31525190 // Save this To Up
The monothiol glutaredoxin GrxD is essential for sensing iron starvation in Aspergillus fumigatus.Efficient adaptation to iron starvation is an essential virulence determinant of the most common human mold pathogen, Aspergillus fumigatus. Here, we demonstrate that the cytosolic monothiol glutaredoxin GrxD plays an essential role in iron sensing in this fungus. Our studies revealed that (i) GrxD is essential for growth; (ii) expression of the encoding gene, grxD, is repressed by the transcription factor SreA in iron replete conditions and upregulated during iron starvation; (iii) during iron starvation but not iron sufficiency, GrxD displays predominant nuclear localization; (iv) downregulation of grxD expression results in de-repression of genes involved in iron-dependent pathways and repression of genes involved in iron acquisition during iron starvation, but did not significantly affect these genes during iron sufficiency; (v) GrxD displays protein-protein interaction with components of the cytosolic iron-sulfur cluster biosynthetic machinery, indicating a role in this process, and with the transcription factors SreA and HapX, which mediate iron regulation of iron acquisition and iron-dependent pathways; (vi) UV-Vis spectra of recombinant HapX or the complex of HapX and GrxD indicate coordination of iron-sulfur clusters; (vii) the cysteine required for iron-sulfur cluster coordination in GrxD is in vitro dispensable for interaction with HapX; and (viii) there is a GrxD-independent mechanism for sensing iron sufficiency by HapX; (ix) inactivation of SreA suppresses the lethal effect caused by GrxD inactivation. Taken together, this study demonstrates that GrxD is crucial for iron homeostasis in A. fumigatus.
1708 related Products with: The monothiol glutaredoxin GrxD is essential for sensing iron starvation in Aspergillus fumigatus.Rabbit Anti-G protein alp Rabbit Anti-APIP Apaf1 In Rabbit Anti-Integrin alph Rabbit Anti-Cell death in FDA Standard Frozen Tissu Rabbit Anti-Integrin alph RABBIT ANTI GSK3 BETA (pS Rabbit Anti-Cell death in MOUSE ANTI HUMAN CD15, Pr Rabbit Anti-Insulin Recep Rabbit Anti-Integrin β2 Rabbit Anti-Cell death in
#31517711 // Save this To Up
Prophylactic treatment in hemophilic patients with inhibitors.: The development of inhibitors continues to be the most important complication in severe hemophilia A. The management of inhibitor patients revolves around two basic principles: eradication of the inhibitor and management and prevention of bleeding. In this paper, we review the prophylactic treatments carried out in the last two decades with the two available bypassing agents and the results of the clinical trials carried out with the new molecules under investigation or already licensed for the prevention of hemorrhagic episodes in hemophilia, like emicizumab.
PLX-4032 Mechanisms: B-Ra DiscoveryPak™ PI 3 Kina PathwayReady™ EGFR Sign Syringe pump can be contr Dabrafenib Mesylate Mecha DiscoveryPak™ EGFR Tyro DiscoveryPak™ Stem Cell DiscoveryPak™ Hedgehog PathwayReady™ MAP Kinas Piperlongumine inhibitors PLX-4720 Mechanisms: B-Ra PathwayReady™ PI3 K Akt
#31506285 // Save this To Up
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX. In phase 3 clinical trials, changes introduced during the bioengineering of VA resulted in the development of undesired anti-drug antibodies in some patients, leading to the termination of a potentially promising therapeutic protein product. Here, we use preclinical biomarkers associated with clinical immunogenicity to validate our deimmunization strategy applied to this bioengineered rFVIIa analog. The reengineered rFVIIa analog variants retained increased intrinsic thrombin generation activity but did not elicit T-cell responses in peripheral blood mononuclear cells isolated from 50 HLA typed subjects representing the human population. Our algorithm, rational immunogenicity determination, offers a broadly applicable deimmunizing strategy for bioengineered proteins.
2349 related Products with: Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.Recombinant Human Factor BAFF(B cell activating fa Human Stem Cell Factor SC Human Stromal Cell-Derive BAFF (B cell activating f CELLKINES PLATELET DERIVE BAFF (B cell activating f Human Factor VIIa 0.1mg Recombinant Human Factor Macrophage Colony Stimula Human Stromal Cell-Derive Epidermal Growth Factor (
#31496264 // Save this To Up
In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.Patients with von Willebrand disease (VWD) often require treatment with supplemental von Willebrand factor (VWF) prior to procedures or to treat bleeding. Commercial VWF concentrates and more recently recombinant human VWF (rVWF) have replaced cryoprecipitate as the mainstay of therapy. In comparison with cryoprecipitate, the VWF content and multimer distribution under current manufacturing processes of these commercial products has not been reported. We measured the factor VIII (FVIII:C), VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CB), VWF platelet-binding activity by GPIbM enzyme-linked immunosorbent assay (VWF:GPIbM), and percentage of high-molecular-weight (HMWM) VWF in 3 pools of group A and O cryoprecipitate, 3 vials of VWF concentrate (Humate-P), and 1 lot of rVWF (Vonvendi). We found that both group O and group A cryoprecipitate have significantly higher ratios of VWF:GPIbM activity and FVIII:C activity relative to VWF:Ag and have better preservation of HMWM than Humate-P. Although not compared statistically, rVWF appears to have more HMWM VWF and a higher ratio of VWF:GPIbM to VWF:Ag than Humate-P and cryoprecipitate. The estimated acquisition cost for our hospital for treating one major bleeding episode was more than 4-fold higher with Humate-P and 7- to 10-fold higher with rVWF than with cryoprecipitate.
1972 related Products with: In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.Recombinant Human Intrins Recombinant Human WNT Inh Recombinant Human Intrins Macrophage Colony Stimula Recombinant Human WNT Inh Recombinant Human Intrins Macrophage Colony Stimula Recombinant Human WNT Inh Goat Anti-Human Tissue Fa TGF beta induced factor 2 Human Insulin-like Growth Human Insulin-like Growth
#31495135 // Save this To Up
[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].To compare the differences in population pharmacokinetic (PK) parameters between two recombinant coagulation factor Ⅷ (FⅧ) preparations, Kogenate FS and Advate, in patients with hemophilia A, and to provide the theoretical basis of precise individualized treatment for those patients. Patients with moderate or severe hemophilia A who had at least one injection of Kogenate FS or Advate at 41 international hemophilia centers were enrolled as subjects from the WAPPS-Hemo project since January 2015 to December 2017. The half-lives of the two drugs and the time of FⅧ activity reaching 2% (TAT 2%) were calculated, and the differences of PK between the two drugs among different age and dose subgroups were further analyzed. ①The mean age of patients in the Kogenate FS (=117) and Advate groups (=120) were (27.6±17.7) and (23.4±16.2) years old, respectively. All patients in the two groups were males. ②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively. ③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively. In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively. ④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively. In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively. The PK parameters of Kogenate FS are superior to those of Advate among different age and dose subgroups.
2393 related Products with: [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].Recombinant Human WNT Inh Recombinant Human Intrins Macrophage Colony Stimula Recombinant Human WNT Inh Recombinant Human Intrins Recombinant Human Coagula Macrophage Colony Stimula Recombinant Human WNT Inh Recombinant Human Intrins Recombinant Human Coagula Recombinant Human Fibrobl Recombinant Human Interle
#31421012 // Save this To Up
A cost-effective approach to factor assay calibration using a truncated live calibration curve.The measurements of clotting factor activities are usually performed using a one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). Advances in automated coagulation analysers have led to the utilization of stored calibration curves. There are sometimes substantial intervals between test calibration and analysis of samples. Variability in results can be influenced by calibrant and methodology. Several guidelines recommend calibration and patient samples be performed together in parallel; this incurs costs, but reliance on a stored calibration curve may lead to inaccuracy of results over time.
2774 related Products with: A cost-effective approach to factor assay calibration using a truncated live calibration curve.ENZYMATIC ASSAY KITS (CH Mouse Factor X total anti Total Antioxidant Capacit Total Mouse uPA Antigen A LIVER DISEASES Total Bile Cell Meter™ Live Cell C Live Bacterial Gram Stain MarkerGene™ LysoLive™ EpiQuik Total Histone H Mouse Anti-Insulin-Like G Cell Meter™ Live Cell C Glutathione (GSH/GSSG/Tot
#31373431 // Save this To Up
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.The formation of neutralizing antifactor VIII (fVIII) antibodies, called inhibitors, is the most common complication in modern haemophilia A care. Novel non-factor replacement therapies, such as emicizumab, have sought to address the limitations of bypassing agents for bleeding management in patients with inhibitors. However, immune tolerance induction (ITI) remains the primary method for eradicating inhibitors and restoring the hemostatic response to fVIII.
1112 related Products with: Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.EnzyChrom™ Kinase Assay Lung cancer tissue array PDGFA & PLCG1 Protein Pro Stomach cancer test tissu ETS1 & AR Protein Protein Rabbit Anti-Haemophilus i Goat Anti-Human EP4 prost Goat Anti- Sox9a (zebrafi Breast tumor survey tissu SKP1 & CTNNB1 Protein Pro Brain tumor tissue array, PIK3R1 & HRAS Protein Pro
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia